Cannabidiol does not display drug abuse potential in mice behavior

Acta Pharmacologica Sinica
Adrián Viudez-MartínezJorge Manzanares

Abstract

Recent evidence suggests that cannabidiol (CBD) may be useful for the treatment of different neuropsychiatric disorders. However, some controversy regarding its profile as a drug of abuse hampers the further development of basic and clinical studies. In this study, the behavioral profile of CBD as a potential drug of abuse was evaluated in C57BL/6J mice. Reinforcing properties of CBD (15, 30, and 60 mg/kg; i.p.) were assessed using the conditioned place preference (CPP) paradigm. Spontaneous withdrawal symptoms and motor activity in the open field were examined 12 h after the last CBD administration (30 mg/kg/12 h, i.p., 6 days). CBD plasma concentrations were measured at 2, 4, 8, 12, and 24 h after the administration of CBD (30 mg/kg, i.p.). Furthermore, an oral CBD self-administration paradigm (50 mg/kg; CBD water-soluble 1.2 mg/mL) was performed to evaluate whether this drug produced any effects on motivation compared with a non-reinforcing substance (water). We found that CBD failed to induce CPP, withdrawal symptoms, or altered motor behavior 12 h after its administration. At that time, only traces of CBD were detected, ensuring that the lack of alterations in somatic signs and locomotor activity was not due to residual dr...Continue Reading

References

Jan 1, 1991·Psychopharmacology·A W ZuardiJ M Cunha
Jan 1, 1990·Psychopharmacology·F S GuimarãesA W Zuardi
Dec 1, 1963·Tetrahedron·R Mechoulam, Y Shvo
Aug 1, 1981·Journal of Clinical Pharmacology·E A Carlini, J M Cunha
Dec 26, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yossef Itzhak, Julio L Martin
Mar 19, 2003·Journal of Neurochemistry·José M OlivaJorge Manzanares
Apr 21, 2005·European Journal of Pharmacology·Fabrício A Moreira, Francisco S Guimarães
Jul 30, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leonora E LongDavid A Taylor
May 5, 2006·Proceedings of the National Academy of Sciences of the United States of America·Erica J CarrierCecilia J Hillard
Jun 20, 2006·Behavioural Brain Research·Leonardo B M ResstelFrancisco S Guimarães
Aug 1, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Fabrício A MoreiraFrancisco S Guimarães
Sep 11, 2008·Current Pharmaceutical Design·Paola MassiDaniela Parolaro
Sep 20, 2008·Journal of Psychopharmacology·A W ZuardiV Tumas
Jan 7, 2009·Archives of General Psychiatry·Paolo Fusar-PoliPhilip K McGuire
Aug 21, 2009·Human Psychopharmacology·José Alexandre CrippaPaolo Fusar-Poli
Sep 5, 2009·Trends in Pharmacological Sciences·Angelo A IzzoRaphael Mechoulam
Nov 27, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yanhua RenYasmin L Hurd
Dec 17, 2009·British Journal of Pharmacology·T V ZanelatiSâmia R L Joca
Feb 26, 2011·Molecular Pharmacology·Ana María Martín-MorenoMaría L de Ceballos
Mar 18, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Toby T Winton-BrownPhilip K McGuire
Sep 18, 2012·Journal of Psychiatric Research·Alline Cristina CamposFrancisco Silveira Guimarães
Jul 3, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Francisco NavarreteJorge Manzanares
Jul 17, 2013·Addiction Biology·Antonio Ortega-ÁlvaroJorge Manzanares
Aug 29, 2013·Therapeutic Advances in Psychopharmacology·Zerrin Atakan
Sep 23, 2014·Journal of Psychopharmacology·Marcos Hortes N ChagasJosé Alexandre S Crippa
Jul 19, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Angélica Pupin SchiavonRúbia Maria Weffort de Oliveira
Aug 13, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Clementino Ibeas BihBenjamin J Whalley
Sep 6, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Esther M BlessingCharles R Marmar
Dec 29, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Margaret HaneySharon L Walsh

❮ Previous
Next ❯

Citations

Oct 17, 2018·Journal of Psychopharmacology·Adrián Viudez-MartínezJorge Manzanares
Jan 9, 2019·The Annals of Pharmacotherapy·Jeffrey W ChenAllison B Blackmer
Mar 3, 2020·Anxiety, Stress, and Coping·Ana M PeiróJorge Manzanares
May 28, 2019·Frontiers in Behavioral Neuroscience·Eva M SchleicherYvonne Bouter
Jul 19, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Claudia Calpe-LópezMaria A Aguilar
May 28, 2020·Frontiers in Plant Science·Konstantinos A Aliferis, David Bernard-Perron
Nov 25, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ani GasparyanJorge Manzanares
Jan 28, 2021·Journal of Clinical Medicine·Klaudia BerkAdrian Chabowski
Nov 27, 2020·Frontiers in Psychiatry·Francisco NavarreteJorge Manzanares
Apr 29, 2021·Psychopharmacology·Lauren C SmithOlivier George
May 6, 2021·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Vinícia Garzella MetzCamila Simonetti Pase
Jun 8, 2021·Frontiers in Pharmacology·Francisco NavarreteJorge Manzanares
Jul 10, 2020·Pharmacology, Biochemistry, and Behavior·Larissa Alencar RodriguesAndrea Donatti Gallassi
Nov 1, 2020·Pharmacology, Biochemistry, and Behavior·Rose Chesworth, Tim Karl

❮ Previous
Next ❯

Software Mentioned

SMART
SigmaStat
SMART ( Spontaneous Motor Activity Recording and Tracking )
Packwin

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.